Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01DA049843 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
This Phase II randomized controlled trial is testing the efficacy of a cell phone application called START for helping men who use stimulants like methamphetamine to get the most out of their HIV treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| START mHealth Intervention | Experimental | Participants randomized to receive the START mHealth intervention will have access to the mHealth application for 6 months following randomization. |
|
| Website referrals | No Intervention | Participants in this condition will receive no intervention and will have access to a website with resources related to substance use disorder treatment and HIV treatment. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| START mHealth Intervention | Behavioral | The START mHealth intervention is a mobile application that will be downloaded by participants through their mobile phones. The application targets information, motivation, and behavioral skills relevant to ART adherence. Participants will have access to this application for 6 months. |
| Measure | Description | Time Frame |
|---|---|---|
| Unsuppressed HIV Viral Load | Proportion of participants with a viral load > 300 copies/mL from dried blood spot samples | 6 Months |
| Measure | Description | Time Frame |
|---|---|---|
| Unsuppressed Viral Load | Proportion of participants with a viral load > 300 copies/mL from dried blood spot samples | 12 Months |
| Self-Reported Stimulant Use Severity | The Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST) provides validated composite scores indexing the severity of cocaine and amphetamine use (Mild = 0-3; Moderate = 4-26; Severe = 27 or greater). |
Not provided
Exclusion Criteria:
Identifies as male
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Adam W Carrico, PhD | Florida International University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Florida International University | Miami | Florida | 33199 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 39210314 | Derived | Davis-Ewart L, Atkins L, Ghanooni D, Diaz JE, Chuku CC, Balise R, DeVries BA, Miller-Perusse M, Ackley Iii D, Moskowitz JT, McCollister K, Fardone E, Hirshfield S, Horvath KJ, Carrico AW. Supporting treatment adherence for resilience and thriving (START): protocol for a mHealth randomized controlled trial. BMC Public Health. 2024 Aug 29;24(1):2350. doi: 10.1186/s12889-024-19745-7. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D055118 | Medication Adherence |
| ID | Term |
|---|---|
| D010349 | Patient Compliance |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 12 Months |
| Self-Reported Anti-Retroviral Therapy (ART) Adherence | Participants will rate on a visual analogue scale the percentage (0% meaning no adherence to 100% meaning complete adherence) of ART medications that they took in the past 30 days | 12 Months |
| Positive Affect | Mean positive affect score as measured by the modified Differential Emotions Scale (Range 0-104) with higher scores being indicative of higher positive affect. | 12 Months |
| D001519 | Behavior |